ReviewEndocrine2014
Managing Cushing's disease: the state of the art.
Review in Endocrine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.Journal of endocrinological investigation · 2016Guideline
- Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.Endocrine · 2017Trial
- The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center.Endocrine · 2015Trial
- The Sonic Hedgehog Pathway is Activated in Cushing's Disease with USP8 Mutations.Biochemical genetics · 2026Article
- Association of mutation profiles with metastasis in patients with non-small cell lung cancer.Frontiers in oncology · 2024Article
- P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs.Cancers · 2022Article
- Article
- Up-To-Date Magnetic Resonance Imaging Findings for the Diagnosis of Hypothalamic and Pituitary Tumors.Yonago acta medica · 2021Review
- Pituitary magnetic resonance imagingGland surgery · 2020Review
- TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.Journal of cellular and molecular medicine · 2019Article
- Metyrapone treatment in Cushing's syndrome: a real-life study.Endocrine · 2018Article
- Canagliflozin improves obesity and insulin resistance in a diabetic patient with Cushings disease undergoing postoperative steroid therapy: A case report.Biomedical reports · 2018Article
- Identification of recurrent USP48 and BRAF mutations in Cushing's disease.Nature communications · 2018Article
- ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing's syndrome.BMC endocrine disorders · 2018Article
- Follow-up intervals in patients with Cushing's disease: recommendations from a panel of experienced pituitary clinicians.Pituitary · 2017Article
- Roles of Hippocampal Somatostatin Receptor Subtypes in Stress Response and Emotionality.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Article
- Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells.Endocrine · 2017Article
- Diabetes in Cushing Disease.Current diabetes reports · 2017Review
- Pituitary magnetic resonance imaging in Cushing's disease.Endocrine · 2017Review
- The risks of overlooking the diagnosis of secreting pituitary adenomas.Orphanet journal of rare diseases · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cushing's disease is a rare chronic disease caused by a pituitary adenoma, which leads to excess secretion of adrenocorticotropic hormone (ACTH). The over-production of ACTH leads to hyperstimulation of the adrenal glands and a chronic excess of cortisol, resulting in the signs and symptoms of a severe clinical state (Cushing's syndrome) that leads to significant morbidity, negative impacts on the patient's quality of life, and, if untreated, increased mortality. The management of patients with Cushing's disease is complicated by the heterogeneity of the condition, with signs and symptoms that overlap with those of other diseases, and high subclinical incidence rates. Controversies surrounding the tests used for screening and identifying patients with Cushing's disease add to the challenge of patient management. Surgical intervention to remove the adenoma is the first-line treatment for patients with Cushing's disease, but medical therapies are useful in patients who relapse or are unsuitable for surgery. The recent introduction of pasireotide, the first pituitary-directed medical therapy, expands the number of treatment options available for patients with Cushing's disease. This state-of-the-art review aims to provide an overview of the most recent scientific research and clinical information regarding Cushing's disease. Continuing research into improving the diagnosis and treatment of Cushing's disease will help to optimize patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.